Capricor Therapeutics, Inc. CAPR

The company is slated to orally present long-term trial results of deramiocel at the World Muscle Society congress in Hiroshima on October 3.

Patients switching from placebo to Deramiocel recorded 76% slower upper-limb decline and 66% slower decline in elbow-related function.

Capricor Therapeutics is back in focus after fresh analyst work led to sharply revised price targets, with some models now pointing to fair value estimates as high as US$27.00 from US$4.38. These shifts reflect a wide spread in analyst opinion as investors weigh the extended FDA action date for deramiocel, the mixed advisory committee outcome, and new upper limb function data that some research views as important. Read on to see what is driving the competing narratives around Capricor...

– Late-Breaking Data to Include HOPE-3 Delayed-Start and Natural History Analyses Submitted in the Recent Major Amendment to the Deramiocel BLA – – PDUFA Target Action Date of November 22, 2026 – SAN DIEGO, Sept. 17, 2026 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that data from HOPE-3 and its open-label extension (OLE) of Deramiocel, the Compan

Healthcare stocks advanced late Monday afternoon, with the NYSE Healthcare Index up 1.5% and the Sta

Capricor Therapeutics, Inc. (NASDAQ:CAPR) has gained another opportunity to make the case for deramiocel, its experimental cell therapy for Duchenne muscular dystrophy. The FDA extended its review by three months after accepting new 24-month clinical data and additional analyses from the company. The submission supports a refined proposed indication focused on upper limb function, which […]

Healthcare stocks were higher late Tuesday afternoon, with the NYSE Healthcare Index adding 0.6% and

Capricor Therapeutics (NASDAQ:CAPR) shares rose 2. 5% in pre-market trading to $10.

Piper Sandler upgraded Capricor to ‘Overweight’ from ‘Neutral’ and sharply raised the price target to $25, a roughly 150% upside potential from current levels.

Investors are now awaiting extra data from Sarepta’s mid-stage studies in two muscle diseases, facioscapulohumeral muscular dystrophy and myotonic dystrophy.

On August 13, Capricor Therapeutics (NASDAQ:CAPR) held its second-quarter earnings call, just over two weeks after an FDA advisory committee voted 3 to 9 against the company’s bid to treat cardiomyopathy in Duchenne muscular dystrophy patients on July 29. That rejection forced a strategic pivot. Management now plans to amend its Biologics License Application to […]

Capricor said on Monday that the FDA pushed back the deadline to decide on the company’s deramiocel application from August 22 to November 22.